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A novel member ofthe family of G protein-coupled r ceptors has been isolated from a mouse brain eDNA library by ~rcening with polymerase 
chain reaction (PER) generated fragment ofmouse generate DNA amplified using degenerated primers. Sequence omparison demonstrates that 
the encoded protein sequence shows the highest homology tothe 5-HT2 family of receptors. The pharmacolosieai profile of membranes from COS 
cells transfeeted with this eDNA, corresponds to a new 5-HT2-1ike receptor that we propose to call 5-HT2C. Its major sites of expression arc in 
the mouse intestine and heart, also with detectable expression in brain and kidney. We speculate that it could account at least in part for the'atypical' 
functions attributed tothe 5-HTIC/5-HT2 receptors. 
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1. INTRODUCTION 
The aminergie neurotransmitter s otonin is believed 
to play an important role in a multitude of'cognitive and 
behavioral functions and dysfunctions including motor 
control feeding, anxiety° depression, and sexual activity 
[1]. This large diversity of functions is paralleled by the 
pharmacological complexity of serotonin receptors. At 
least four classes have been distinguished pharmacol- 
ogically: 5-HT1, 5-HT2, 5-HT3, and 5-HT4. These cat- 
egories are defined by both binding and effeetor cou- 
pling properties of the receptors [2,3]. More recently, 
molecular biological data have confirmed the existence 
of multiple serotonin receptors° including both ligand- 
gated receptors (5-HT3) and G protein-coupled recep- 
tors (GPRs) [4]. This latter class can be split into two 
classes [5], reflecting the second messenger system to 
which the receptor is coupled: the 5-HT1C and the 5- 
HT2 receptors which are coupled to the activation of 
the phospholipase C, and the 5-HT1A, B and D family, 
which interacts with the adenylyl cyclase; it is possible 
that 5.HT4 belongs to this class, although it has not yet 
been characterized molecularly. To date the adenylyl 
cyelase 5-HTI subclass has been the most extensively 
studied, with more than five subtypes already described 
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[6]. By contrast only two members of the 5-HT2 sub- 
family have been characterized, 5-HTIC and 5-HT2. 
5-HT2 receptors mediate many ofcentrai and periph- 
eral physiological functions of serotonin. Cardiovascu- 
lar effects include contraction of blood vessels and 
shape change in platelets; central nervous ystem effects 
include neuronal sensitization to tactile stimuli and me- 
diation of hallucinogenic effects of lysergic acid diethyl- 
amide and related phenylisopropylamine hallucinogens. 
Many investigator's have observed that 5-HT1C and 
5.HT2 receptors do not reflect all the properties attri- 
buted to them. For example some 5-HT2-1ike effects of 
serotonin on peripheral smooth muscles are classified as 
'atypical' [7]° leading to the hypothesis that other 5-HT2 
receptor subtypes might exist. 
Therefore, we have undertaken the cloning and re- 
combinant expression of new 5-HT2 receptors in the 
mouse in order to stud), their functional properties. Pre- 
vious molecular cloning experiments have demon- 
strated that the 5-HT1 and 5-HT2 receptor subclasses 
are encoded by members of the seven transmembrane 
domain containing ene superfamily. Taking advantage 
of the sequence conservation between related members 
of this family we have screened for new members of the 
5-HT2 class. We describe here the cloning and func- 
tional characterization f a new 5-HT2-1ike receptor. 
2. MATERIALS AND METHODS 
2.1. Drltgs and chumlculs 
Restriction endonucleases, AMV Reverse transcripta~, DNA 
pol:lmera~ 1, T4 polynucleotide kina.~, T4 DNA liga~. T3 or T7 
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RNA polymerase, were purchased from Bethesda Research Laborato- 
ries, New England Biolabs, Boehringer.Mannheim, and Stratagene. 
Sequenase and sequencing reagents were purchased from United 
States Biochemical Corporation. Taq polymerase for PeR was pur- 
chased from Perkin-Elmer-Cetus and reaetiom lxrformed in a Perkin- 
Elmer-terns cycler. Ketanserin, ritanserin and setoperone were kindly 
provided by Janssen (Beerse, Belgium). ICS 205.930 and MDL 72 222 
were gifts from Sandoz (Basel, Switzerland) and MerelI-Dow (Stras- 
bour8, France), respectively. Other neurochemicals were from the 
RBI, or Sigma. a-,p. and 3SS-labeled nucleotides as well as [L2Sl]DOI 
(2200 Ci/mmol), were from New England Nuclear. 
2,2, Statulard molecular biology techniques 
Classical published procedures were used for library sercenin 8 plus- 
mid subcloning, RNA extraction, and COS cell transfections [8]. 
2.3. PCR experiments 
We synthesized degenerated oligonu¢leotides coding for the con- 
served Vlth (a) and VIlth (b and c) transmembrane domains se- 
quenc~ [9]. 
(a) TACCTCG AG G TCG ACG GT I ATGTG G TG { C,T } CCITT- 
{C,T}TT{C,T}AT 
(b) AGAACTAGTGGTACCCA{G,A }[GT {G,A)TAIACIA {G,A) - 
IGG{G,A}TT 
(e) AGA ACTAG TG G TA CC C { G ,C } i A,T } { G,A } CA IAC { G. A } TA- 
ICC{G,A,T}ATCCA 
A polylinker has been added at the 5' end for subcloning. 1~g of 
mouse genomie DNA was denatured 1 rain at 94QC, annealed 2 rain 
at 55°C, and amplified 3rain at 72°C in the presence of 3 mM MgCI, 
lbr 20 cycles for the first t we sets of primers (a and b, l ~tg each). 1/10th 
of the reaction was reamplified with the first and third set of primers 
(a and c, 1 gg each) for 20 more cycles under the same conditions, 
Products were subeloned in pBluescript and sequenced. Oligonucleo. 
tides corresponding to the characterized products were synthesized 
and then used as probes. 
For quantitative RT-PCR experiments, tandard PCR reaction 
buffer was used in the presence of 10/zg of total RNA. After denatu- 
ration, AMV reverse transcriptase (13 U) and Taq polymerase (5U) 
were addS, and ¢~tenfion was done at $0"C for 15 rain and then a 
standard PeR amplification protocol [8] was used. Samples were 
taken after 20, 25, and 30 cycles to ensure that the reaction was in the 
exponential phase of synthesis. We used, as an internal standard, 
primers corresponding to the mRNA of the ribosomal elongation 
factor, EF1A, amplified in the same reaction as the NP75 primers. 
2.4. [ml]bOl binding assays 
[12~I]DOI [ 10] was used as the radioligand to detect expression of the 
NP75 gene product in membrane fractions isolated from COS-7 cells 
48 h after DNA transfection. Briefly, the incubation medium (200 el) 
contained 50 al of radioligand, 50 gl of buffer or of competing drug, 
and 100 gl of mere brane ~asl~nsion (protein concentration, 50htg/ml). 
The mixture was incubated at 30oc for 30 rain, The assay was termi- 
nated by addition of'ice-cold iso.osmotle solution, and rapid filtration 
through GF/B filters, followed by 4 washes of 5 ml of ice.cold buffer. 
Filters were dried rapidly and their radioactivity determined by liquid 
scintillation counting. Non.specific binding, determined in the pres- 
ence of 10gM unlabeled DOI, represented about 30% of total binding. 
Competition studies for [~-'~l]DOl-binding were performed by add- 
ins increasing coa~ntrations of test drug to the reaction. 
Data were analyzed using the iterative non-linear regression fitting 
program LIGAND (Version 3.0, MePershon 1985) and RSI (Release 
4.0). 
3. RESULTS AND DISCUSSION 
G protein-coupled receptors hare extensive homol- 
ogy at the amino acid level, especially within the t.rans- 
membrane region. The sixth and seventh transmem- 
brahe domains present he highest score of homology 
between several members of this family of receptors [9]. 
We therefore designed degenerated oligonucleotides, to 
perform PCR reactions on mouse genomic DNA.  Sev- 
eral genomic fragments whose sequences were similar to 
known OPRs were obtained, and subcloned. Some of 
these products were identical to the already cloned 
mouse serotonin receptors [11]. Among these products 
a novel sequence, NP75, was identified as the most sim- 
ilar to the 5-HT2 sequence. This we used to screen a 
mouse brain eDNA library. 
The complete NP75 eDNA contains an open reading 
frame of 1510 bp encoding a protein of 504 amino acids 
with a predicted molecular weight of 56,508 Da (Fig. 1). 
On the. basis of the hydropathy plot (not shown), this 
protein displays seven hydrophobic domains, and has 
extensive homology with other members of the GPR 
family, including one potential N-glycosylation site at 
its amino terminus (Fig. 1), and consensus sequences for 
phosphorylation by different protein kinases in the cy- 
toplasmic regions. In addition the pre~ence of 19 Ser or 
Thr residues in the 121 carboxyterminal residues (Fig. 
1) may indicate that this region is involved in the recep- 
tor desensitization byprotein kinases as has been dem- 
onstrated for the fl-adrenergie r ceptor [12]. 
When compared with other GPRs, the NP75 traits- 
membrane region exhibits high degree of homology 
with the 5-HT2 and 5-HT1C receptors, especially within 
domains II and III where 12 and 20 amino acids, respec- 
tivdy, are identical. Alignment of the transmcmbrane 
region of various aminergic receptors uggests that the, 
NP75 receptor belongs to the 5-HT2 subfamily [5], 
being slightly more divergent from 5-HT1C than from 
5-HT2; homologies reach 60% with the mouse 5-HT2 
receptor [11] and 57% with the mouse 5-HT1C [13]. 
Compared to the rat 5-HTIA receptor [14], or mouse 
5-HT1B receptor [8] the homology is less than 30%. By 
comparison, the homologies between 5-HT2 and 5- 
HTIC receptor of the same species are around 70%, and 
the 5-HT2 receptors fi'om different species have homol- 
ogies over 90%. In addition, the NP75 gene includes two 
introns (not shown), which are present at equivalent 
positions to the introns in the 5-HT2 gene ill]. This 
confirms a probable common evolutionary origin, dif- 
ferent from the other 5-HT1 genes which are devoid of 
introns. In order to confirm that this clone represents 
a new member of the 5-HT2 family we analysed it fur- 
ther by expression studies. 
To determine the pharmacological properties of the 
predicted NP75 protein, the coding sequence of the 
eDNA was introduced into the eucaryotic vector pSG5 
[l 5] and transfected into COS-7 cells, whose membranes 
were then tested for their binding properties. Steady- 
state binding assays with ,l~ . . . . . . .  L - l ]~t  uemonswat~u that 
this ligand interacts specifically with the recombinant- 
transfected membrane preparation (and not to mock 
transfected cells) with high affinity and in a saturable 
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Fig. 1. Sequence of the NP75 eDNA. The NP75 eDNA and deduced protein sequences are displayed. Roman numbers over the boxes localize the 
transmembrane domains. The left numberin8 isfor the DNA sequence, the right is for the protein. In frame stop codons are ~hown by *. The circled 
N indicates putative N-glycosylation sites. Circled serincs or thrconines represent consensus for phosphorylation by protein kina~ A (A), protein 
kinase C (C), and casein kinase (K). 
fashion (Fig. 2). The resulting saturation data exhibits 
a best-fit to a single site mode with an apparent K~ of  
25.8 _ 0.54 nM (n = 3). The apparent B~ varied be- 
tween 14.8 and 21.0 pme! /mg protein depending on the 
transfection etticiency. The Kd values of  DOI  for classi- 
cal 5-HT2 receptor is 2.2 nM [10]. 
Competit ive inhibition studies were performed in 
order to refine the pharmacological profile of  this re- 
ceptor. Table 1 shows the following rank order of  poten- 
cies for selected rugs: Ritanserin > N-aeetyi 5 -HT > 
Methysergide > Setup°rune = Cyproheptadine > 
Spiperone > Ketanserin > Tryptamine > 5-HT > 8-CH- 
DPAT.  This rank order as well as the apparent Kd 
values for these compounds correlate with those of  5- 
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Fig, 2, Saturation binding of NP75 COS transfected membranes, The 
scatehard plot of the dose binding curves with [~"~I]DOI as radioligand 
is represented with each value as the mean of at least 3 independent 
trials run in triplicate. The mean Ka value and the maximal binding 
capacity value are respectively 25.8 nM and 18,4 pmol/mg of protein. 
HT2 (P = 0.0436) or 5-HT1C (P = 0.022) (Kendall  rank 
correlation), but not with other 5-HT2 receptor sub- 
types (P > 0.05): the low affinity of  this receptor for 
serotonin would place i: in the 5-HT2 family of  recep- 
tors, that is confirmed by the low affinity for the 5- 
HT1A selective agonist 8-OH-DPAT.  In addition the 
Table 1 
Pharmacology of the mouse 5-HT receptor expressed in COS cells 
Drug COS cell 5-HT2 5-HT 1C 
bindlng 
Agonists 
5-HT 5.90 5.5 7,5 
2-Me-5-HT 5.18 5.2 5.8 
Tryptamine 6.70 6.0 7.2 
I-Me-5-HT 5.60 6.3 8.4 
NNdiMe-5-MeOT 5.13 6.2 7.0 
8-OH-DPAT 5.19 5.0 5.2 
Quipazine 5,18 6.2 6,7 
Histamine <4,0 <4.0 <4.0 
Antagonists 
Ritanserln 8.44 9.3 8.6 
Mothysergide 7.90 8,6 8,6 
Setoperone 7.61 8.6 7.3 
Cyproheptadlne 7,65 8.5 7,9 
Spiperone 7.30 8.8 5.9 
Ketanserin 6.69 8.9 7,0 
ItS 205-930 :5.30 5.3 4,6 
MDL72222 4.62 6.7 <5.0 
Chlorpromazine <4.0 <4.0 <4,0 
Competition experiment for [~-'~I]DOI labeled membrane from NP75 
transl'ected COS cells as compared with published values for native rat 
5-HTIC and 5-HT2 n.-~eptor taken from [221. Each value, expressed 
as pK. (-log reel/l) is the mean of at least 3 independent trial runs in 
triplicate. 
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Fig. 3. RT-PCR analysis of NP75 in vivo expression. PeR ex~ri- 
ments were done in the presence of 10 pg of total RNA. using NP75 
and EFIA specific primers. PCR products were analyzed and revealed 
by h~,bridization to z"P-labeled primers different fi'om tile amplimers, 
after 25 cycles for NP75 (row NP75) or after 20 cycles for EFIA (row 
EFIA). The resulting autoradiograms were scanned and the EFIA 
normalized intensity isdisplayed (lower panel). Lane 1 contains RNA 
from LMTK cell line; lane 2, from 10.5 days mouse mbryo; lane 3, 
from mouse testis; lane 4, from 3T6 cell line; lane 5, from MBK cell 
line; lane 6. from mouse liver; !are 7, from mouse cerebellum; lane 8, 
from mouse heart; lane 9, from mouse intestine; lane 10, from mouse 
spleen; lane 11, fi'om mouse kidney; arid inne 12, from total mouse 
brain, 
poor competit ion by the 5-HT3 selective compounds 
ICS 205-930, MDL 72222, and quipazine rule out the 
possibility that this belongs to the S-HT3 family. The 
receptor affinity for ketanserin is too low for it to be a 
typical 5-HT2, although the high affinity that it has for 
the 5-HT2 antagonist ritanserin makes it difficult to 
classify NP75 within the 5-HT2/5-HT1C family. Fur- 
thermore, preliminary evidence shows that like 5-HT2 
and 5 -HT IC  receptors, NP75 is coupled to the PLC 
second messenger system (not shown). 
The heterogeneity of  5-HT2 receptors has already 
been detected on preparations of cortical membranes, 
where the agonist competit ion curves for [3H]ketanserin 
are shallow, indicating the presence of two types of 
binding site. The observation that the high affin'.'ty sites 
represented only a small subtraction of  the ketanserin 
sites in addition to the existence of tissues containing 
only low affinity binding sites for the amphetamine de- 
rivative 4-bromo-2,5-dimethoxyphenylisopropylamine 
(DOB) led Peroutka and coworkers to propose the hy- 
pothesis that the high affinity agonist DOB binding 
must represent a unique receptor subtype 5-HT2A, 
whereas the low-affinity site (labeled by ketanserin but 
not by DOB) 5-HT2B represents the classical 5-HT2 
receptor [16]. The low affinity of  the NP75 receptor for 
ketanserin makes it unlikely to correspond to any one 
of  these subtypes. Therefore this new receptor appears 
distinct from the 5-HTIC,  5-HT2A, and 5-HT2B, so we 
propose to call it 5-HT2C. 
In order to have more complete information concern- 
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ing the properties of this new serotonin receptor, we 
analyzed for its in vivo expression. NP75 transcripts 
were analyzed by Northern blot (not shown) and by 
quantitative RT-PCR experiments. Fig. 3 displays the 
pattern of expression of NP75 seen after 25 cycles of 
amplification using 10/~g of total RNA. The highest 
expression is detected in the mouse intestine and in the 
mouse heart as well as at a lower level in the brain and 
kidney. In contrast, no expression isseen in the liver and 
spleen. We used the ribosomal elongation factor EF1A 
as an internal standard and primers located in two dif- 
ferent exons in order to distinguish the amplification of 
RNA from DNA templates. The NP75 mRNA is also 
detected in the mouse embryo at day 10.5, and in the 
kidney derived cell line BHK. In situ experiments in the 
mouse brain as well as in the heart and intestine are in 
progress in order to refine these results. 
The localization of this receptor to peripheral as well 
as to the central nervous ystem is puzzling. However, 
several reports have provided evidence that the periph- 
eral action of serotonin cannot be mediated by the clas- 
sical 5-HTIC or 5-HT2 receptors. For example, in the 
rat, administration of 5-HT causes tachycardia. This 
effect is antagonized by ketanserin, cyproheptadine, 
methysergide and metiothepine. Since DOI which ex- 
hibits a partial agonist action with 5-HT2 receptors, 
neither mimics nor blocks this taehycardiae ction, the 
5-HT2 receptor involved has been classified as 'atypical' 
[7]. In addition coronary vasoconstriction has been 
shown in several species to be mediated by a 5-HT2-1ike 
receptor [17], effects which are potentiated in coronary 
artery disease [7]. Similarly, the contractions of the rat 
stomach are mediated by an unknown serotonin recep- 
tor [18]. Furthermcre0 the activation of the peripheral 
serotonin receptor in platelets and in vascular smooth 
muscle has been shown to stimulate PI turnover. Never- 
theless, mRNA analysis from several peripheral tissues, 
including heart and intestine, has failed to detect spe- 
cific transcripts for either the 5-HT2C or the 5-HT2 
receptor [19]. Therefore, we propose that some of the 
peripheral actions of 5-HT0 specifically on smooth mus- 
cles, are mediated by the NP75 receptor. 
Development of specific drugs to NP75/5-HT2C re- 
ceptor could be used therapeutically in some eases of 
human cardiac pathology. For example, the recent find- 
ing that serotonin, known to have a vasodilating effect 
on normal human coronary arteries, has a direct vaso. 
constr;.cting effect via 5-HT2-1ike receptors when the 
endothelium is damaged, (as in coronary artery disease) 
[20], makes it urgent o characterize in more detail the 
receptors involved. 
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